Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice

Fig. 4

HMGN1 promoted DC-dependent CD8+ T cell expansion ex vivo. a The experimental design of CD8+ T cell expansion through CD3/CD28 stimulation or DC co-culture. b A CD8+ T cell expansion assay of co-culturing naïve Pmel-1 CD8+ T cells with Ly5.1+ gp100-specified BMDCs. After 48-h co-culture, the 13% increase in number of generation (G) ≥ 2, CD25+ CD90.1+ CD8+ T cells in control and the 20.9% increase in mH-added group. c The cell number of CD25+ CD8+ T cells in G ≥ 2 cell generation. d The CD8+ T cell expansion assay of stimulating naïve Pmel-1 CD8+ T cells by using anti-CD3 antibody and anti-CD28 antibody. After 72-h stimulation, the 55.4% increase in number of G ≥ 2, CD25+ CD90.1+ CD8+ T cells in control and the 53.4% increase in mH-added group. Each result is representative of three independent experiments. Data are presented as mean ± SEM. A Student’s t-test is used to compare the statistically significant difference between the mH-added and mH-unadded groups

Back to article page